Monoclonal antibodies

Monoclonal antibodies (mAbs) are advancing applications across healthcare, environmental, agricultural, and life sciences industries. In therapeutics, mAbs play a crucial role in cancer treatments, targeting specific tumor antigens and enhancing immune responses. Beyond oncology, they're used in treating autoimmune disorders and infectious diseases. Process development optimizes cell culture conditions, purification methods, and production scaling for both therapeutic and research applications. This technology enables sensitive solutions in areas like pharmaceutical research, targeted drug delivery, and environmental pollutant monitoring. From cancer immunotherapies to food authenticity testing, mAbs are driving innovation in therapeutics, diagnostics, and research methodologies across diverse fields.

Monoclonal antibodies

Monoclonal antibodies (mAbs) are advancing applications across healthcare, environmental, agricultural, and life sciences industries. In therapeutics, mAbs play a crucial role in cancer treatments, targeting specific tumor antigens and enhancing immune responses. Beyond oncology, they're used in treating autoimmune disorders and infectious diseases. Process development optimizes cell culture conditions, purification methods, and production scaling for both therapeutic and research applications. This technology enables sensitive solutions in areas like pharmaceutical research, targeted drug delivery, and environmental pollutant monitoring. From cancer immunotherapies to food authenticity testing, mAbs are driving innovation in therapeutics, diagnostics, and research methodologies across diverse fields.
INFORS HT solutions for mAbs

Advancing monoclonal antibody development for diverse applications

mAb research spans various industries, from environmental monitoring to life sciences. In the early stages, researchers focus on antibody discovery and engineering, aiming to optimize binding affinity and specificity for diverse targets. This involves screening large antibody libraries and employing protein engineering techniques to fine-tune molecular interactions. 

Process development builds on these initial findings, addressing challenges in scalability and reproducibility. Scientists work on optimizing cell line development, culture conditions, and purification methods. This stage involves balancing yield, product quality, and cost-effectiveness while adhering to industry-specific regulatory requirements. 

Maintaining mAb stability and functionality throughout development is crucial. Researchers investigate formulation strategies and analyze critical quality attributes for consistent application performance. This meticulous approach supports the creation of reliable tools for environmental pollutant detection, agricultural diagnostics, pharmaceutical research, and food safety testing. 




Monoclonal antibodies challenges

Inline SVG icon

Antibody discovery and optimization

Identifying and engineering monoclonal antibodies with optimal specificity, affinity, and stability presents significant challenges. Researchers must efficiently screen vast antibody libraries and characterize promising candidates. The optimization process requires balancing multiple factors, including potency, manufacturability, and safety profiles. Scientists face the ongoing challenge of enhancing desired characteristics while minimizing issues such as off-target binding and immunogenicity. This complex, iterative process demands advanced techniques and careful consideration to develop antibodies suitable for diverse applications.

Inline SVG icon

Scalability and consistency

As projects progress from early research to process development, maintaining product quality and efficiency becomes increasingly complex. Researchers must develop robust bioprocesses that can be reliably scaled up, encompassing cell line development, upstream and downstream processing, and formulation. The challenge lies in minimizing variability across different production scales, as inconsistencies can significantly impact the quality, efficacy, and safety of the final antibody product. This requires careful optimization of multiple parameters to ensure consistency between batches at increasing scales.

Inline SVG icon

Regulatory compliance and quality control

Navigating regulatory requirements and maintaining rigorous quality control present ongoing challenges in mAb development. Researchers must adhere to complex guidelines set by regulatory authorities across different regions, ensuring compliance throughout the development process. This involves implementing comprehensive testing protocols for purity, potency, and safety, while also validating manufacturing processes. The challenge extends to creating and maintaining extensive documentation systems that meet evolving regulatory standards. Balancing these requirements with the need for efficient development and production processes demands careful planning and resource allocation, impacting timelines and costs throughout the mAb development lifecycle.

Inline SVG icon

Antibody discovery and optimization

Identifying and engineering monoclonal antibodies with optimal specificity, affinity, and stability presents significant challenges. Researchers must efficiently screen vast antibody libraries and characterize promising candidates. The optimization process requires balancing multiple factors, including potency, manufacturability, and safety profiles. Scientists face the ongoing challenge of enhancing desired characteristics while minimizing issues such as off-target binding and immunogenicity. This complex, iterative process demands advanced techniques and careful consideration to develop antibodies suitable for diverse applications.

Inline SVG icon

Scalability and consistency

As projects progress from early research to process development, maintaining product quality and efficiency becomes increasingly complex. Researchers must develop robust bioprocesses that can be reliably scaled up, encompassing cell line development, upstream and downstream processing, and formulation. The challenge lies in minimizing variability across different production scales, as inconsistencies can significantly impact the quality, efficacy, and safety of the final antibody product. This requires careful optimization of multiple parameters to ensure consistency between batches at increasing scales.

Inline SVG icon

Regulatory compliance and quality control

Navigating regulatory requirements and maintaining rigorous quality control present ongoing challenges in mAb development. Researchers must adhere to complex guidelines set by regulatory authorities across different regions, ensuring compliance throughout the development process. This involves implementing comprehensive testing protocols for purity, potency, and safety, while also validating manufacturing processes. The challenge extends to creating and maintaining extensive documentation systems that meet evolving regulatory standards. Balancing these requirements with the need for efficient development and production processes demands careful planning and resource allocation, impacting timelines and costs throughout the mAb development lifecycle.

INFORS HT solution for monoclonal antibody production 


Incubator shaker

Multitron

The INFORS HT Multitron incubator shaker addresses key challenges in mAb development by delivering consistent performance, allowing researchers to focus their efforts on process design and optimization. This reliability supports antibody discovery by enabling high-throughput screening with stable cultivation conditions. The system's precise control over temperature, humidity, and CO2 levels maintains optimal environments for antibody-producing cell cultures, freeing scientists to concentrate on critical experimental variables. This consistency contributes to improved reproducibility and scalability, essential factors in regulatory compliance and quality control. The Multitron's flexibility accommodates various culture volumes, facilitating seamless progression from initial discovery to optimization phases, thus streamlining the entire process development workflow. 

Incubator shaker

Minitron

The INFORS HT Minitron incubator shaker addresses mAb development challenges in space-constrained environments. It supports initial screening and optimization stages with precise environmental control. The Minitron's robust direct drive ensures consistent shaking, promoting uniform cell suspension crucial for reproducible results. Its compact design makes it ideal for preliminary studies or specialized projects, while maintaining the level of control necessary for mAb research. These features contribute to reliability in early-stage development, supporting efficient process optimization and adherence to regulatory standards, even when working with smaller culture volumes. 

Bioreactors

INFORS HT bioreactors address key challenges in early-stage mAb process development. These systems offer precise control of critical parameters, supporting antibody discovery and optimization. The eve® software platform enables comprehensive bioprocess management. Their modular design provides flexibility across scales, while integrated sensors facilitate real-time monitoring. These features enhance cell line development, process optimization, and data quality, supporting reproducibility and regulatory compliance in mAb research. 

Customer testimonial

Delivering excellence in antibody discovery

INFORS HT partners with FairJourney Biologics, an innovative contract research organization (CRO) to deliver excellence in antibody discovery and production.

Related articles

See all
05 Dec 20243 min read0
Back to Basics: Understanding UV decontamination in incubator shakers

Maintaining a sterile environment is essential in bioprocess laboratories, particularly when working with sensitive cell cultures or microbial samples. Contamination not only jeopardizes experimental results, but it can also lead to costly downtime and wasted resources. In this first installment of our Back to Basics blog series, we focus on the role of UV decontamination in incubator shakers and how it serves as an effective risk mitigation strategy. 

25 Nov 202438 min read
Cell-free gene expression in bioprinted fluidic networks

Researchers from the School of Natural Sciences at TU Munich utilized the Minifors bench-top bioreactor to support their innovative experiment on cell-free gene expression in bioprinted fluidic networks. This study highlights how integrating cell-free protein synthesis into vascularized hydrogels enables dynamic molecular control, providing valuable insights for creating synthetic biomaterials that mimic biological functions.

25 Nov 202433 min read
Production and evaluation of a new set of recombinant antigens for the serological diagnosis of human cysticercosis

Researchers from the Department of Parasitology-Mycology at Institut Pasteur de Côte d'Ivoire are exploring new solutions for diagnosing human cysticercosis in remote areas. Their study tested a set of recombinant antigens for use in ELISA assays as a low-cost alternative to neuroimaging. While some challenges remain in optimizing sensitivity, the results show great promise, particularly in regions with limited medical resources. These antigens could provide a crucial screening tool for detecting neurocysticercosis, especially in patients with epilepsy, helping those in remote areas access better diagnosis and care.

05 Dec 20243 min read0
Back to Basics: Understanding UV decontamination in incubator shakers

Maintaining a sterile environment is essential in bioprocess laboratories, particularly when working with sensitive cell cultures or microbial samples. Contamination not only jeopardizes experimental results, but it can also lead to costly downtime and wasted resources. In this first installment of our Back to Basics blog series, we focus on the role of UV decontamination in incubator shakers and how it serves as an effective risk mitigation strategy. 

25 Nov 202438 min read
Cell-free gene expression in bioprinted fluidic networks

Researchers from the School of Natural Sciences at TU Munich utilized the Minifors bench-top bioreactor to support their innovative experiment on cell-free gene expression in bioprinted fluidic networks. This study highlights how integrating cell-free protein synthesis into vascularized hydrogels enables dynamic molecular control, providing valuable insights for creating synthetic biomaterials that mimic biological functions.

25 Nov 202433 min read
Production and evaluation of a new set of recombinant antigens for the serological diagnosis of human cysticercosis

Researchers from the Department of Parasitology-Mycology at Institut Pasteur de Côte d'Ivoire are exploring new solutions for diagnosing human cysticercosis in remote areas. Their study tested a set of recombinant antigens for use in ELISA assays as a low-cost alternative to neuroimaging. While some challenges remain in optimizing sensitivity, the results show great promise, particularly in regions with limited medical resources. These antigens could provide a crucial screening tool for detecting neurocysticercosis, especially in patients with epilepsy, helping those in remote areas access better diagnosis and care.

Consult with our experts

Interested to learn how INFORS HT technologies could help optimize your mAb production? Reach out to us today.

We care about your privacy

We use cookies to improve user experience. We analyse our traffic, we personalise content and ads on our website, and we provide social media features. Certain cookies are necessary for our website to work properly and to enable you to use its features. With your consent, we also use analytics cookies to improve our website and marketing cookies to display advertisements and content on our website. 
Cookie settings